Drug discovery CRO MercachemSyncom adds biology services through acquisition - Gilde Healthcare

Drug discovery CRO MercachemSyncom adds biology services through acquisition

November 9, 2020

Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje (Sweden). The acquisition of Admescope allows MercachemSyncom to significantly expand its service offering with tailor-made-in-vitro ADME-tox studies for pre-clinical and early clinical R&D projects. MercachemSyncom expects seamless integration with its existing medicinal, synthetic and development chemistry capabilities.

Admescope, founded in 2011, brings world-class expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Its experienced scientific and management teams have executed ADME-Tox studies for pharma and biotech clients across the world.

Eelco Ebbers, CEO of MercachemSyncom, commented,

“We are pleased to welcome our new colleagues fom Admescope. The high quality, innovative and client-centric ADME-Tox services of Admescope represent a perfect, complimentary match with our organization. The addition of Admescope to MercachemSyncom marks an exciting year for our company. The expansion of our cGMP manufacturing apabilities via the acquisition of our Weert site at the beginning of the year has had an extremely positive effect on our business and client base, resulting in a record year in terms of medicinal and synthetic chemistry services.”

Rafael Natanek, Partner at Gilde Healthcare, commented,

“This is the third acquisition since our investment in MercachemSyncom, executing our active buy-and-build agenda to complement the strong organic growth of the company. Admescope adds specialized biology services to MercachemSyncom and enables integrated contract research services from hit-finding to Phase 2a. Combined with the acquisition of Alcami Weert last year, Admescope further solidifies MercachemSyncom’s position as the premier mid-sized drug discovery CRO in Europe.”

About MercachemSyncom

MercachemSyncom is the leading mid-sized European contract research organization offering innovative chemistry, medicinal chemistry, ADME-Tox, early drug substance development, and GMP production services to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom offers integrated drug-discovery services from hit to clinic. Working for many pharmaceutical and biotech companies throughout the world, MercachemSyncom is recognized for its high-quality products and services and its unprecedented problem-solving capabilities. For more information, visit the company’s website at www.mercachemsyncom.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022